RU2010131172A - THERAPEUTIC METHODS FOR TREATING CANCER - Google Patents
THERAPEUTIC METHODS FOR TREATING CANCER Download PDFInfo
- Publication number
- RU2010131172A RU2010131172A RU2010131172/15A RU2010131172A RU2010131172A RU 2010131172 A RU2010131172 A RU 2010131172A RU 2010131172/15 A RU2010131172/15 A RU 2010131172/15A RU 2010131172 A RU2010131172 A RU 2010131172A RU 2010131172 A RU2010131172 A RU 2010131172A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- chemotherapeutic agent
- hedgehog
- patient
- lung cancer
- Prior art date
Links
Abstract
1. Способ продления безрецидивного периода жизни у пациента с раком, которого подвергают лечению химиотерапевтическим средством, включающий введение этому пациенту терапевтически эффективного количества ингибитора хеджехог (hedgehog). ! 2. Способ по п.1, в котором ингибитор хеджехог вводят параллельно с химиотерапевтическим средством. ! 3. Способ по п.2, в котором введение ингибитора хеджехог продолжают после прекращения лечения химиотерапевтическим средством. ! 4. Способ по п.1, в котором ингибитор хеджехог вводят после прекращения лечения химиотерапевтическим средством. ! 5. Способ по любому из пп.1-4, в котором рак выбран из рака легкого, рака мочевого пузыря, рака яичников, рака толстой кишки, рака молочной железы, рака предстательной железы, множественной миеломы, острого миелогенного лейкоза и хронического миелогенного лейкоза. ! 6. Способ по п.5, в котором рак легкого выбран из мелкоклеточного рака легкого и немелкоклеточного рака легкого. ! 7. Способ по любому из пп.1-4, в котором рак представляет собой мелкоклеточный рак легкого, и химиотерапевтическое средство выбрано из этопозида, карбоплатины, цисплатины, иринотекана, топотекана, гемцитабина, лучевой терапии и их комбинаций. ! 8. Способ по любому из пп.1-4, в котором рак представляет собой немелкоклеточный рак легкого, и химиотерапевтическое средство выбрано из винорелбина, цисплатины, доцетаксела, пеметрекседа, этопозида, гемцитабина, карбоплатины, бевацизумаба, гефитиниба, эрлотиниба, цетуксимаба, лучевой терапии и их комбинаций. ! 9. Способ по любому из пп.1-4, в котором рак представляет собой рак мочевого пузыря, и химиотерапевтическое средство выбрано из гемци 1. A method of extending a disease-free life span in a patient with cancer who is being treated with a chemotherapeutic agent, comprising administering to the patient a therapeutically effective amount of a hedgehog inhibitor. ! 2. The method according to claim 1, in which the hedgehog inhibitor is administered in parallel with a chemotherapeutic agent. ! 3. The method according to claim 2, in which the introduction of a hedgehog inhibitor is continued after treatment with a chemotherapeutic agent is discontinued. ! 4. The method according to claim 1, in which the hedgehog inhibitor is administered after cessation of treatment with a chemotherapeutic agent. ! 5. The method according to any one of claims 1 to 4, wherein the cancer is selected from lung cancer, bladder cancer, ovarian cancer, colon cancer, breast cancer, prostate cancer, multiple myeloma, acute myelogenous leukemia and chronic myelogenous leukemia. ! 6. The method according to claim 5, in which the lung cancer is selected from small cell lung cancer and non-small cell lung cancer. ! 7. The method according to any one of claims 1 to 4, in which the cancer is small cell lung cancer, and the chemotherapeutic agent is selected from etoposide, carboplatin, cisplatin, irinotecan, topotecan, gemcitabine, radiation therapy, and combinations thereof. ! 8. The method according to any one of claims 1 to 4, in which the cancer is non-small cell lung cancer, and the chemotherapeutic agent is selected from vinorelbine, cisplatin, docetaxel, pemetrexed, etoposide, gemcitabine, carboplatin, bevacizumab, gefitinib, erlotinib, cetuximab and their combinations. ! 9. The method according to any one of claims 1 to 4, in which the cancer is bladder cancer, and the chemotherapeutic agent is selected from gemtsi
Claims (37)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1716007P | 2007-12-27 | 2007-12-27 | |
US11/965,688 | 2007-12-27 | ||
US61/017,160 | 2007-12-27 | ||
US11/965,688 US7812164B2 (en) | 2006-12-28 | 2007-12-27 | Cyclopamine analogs |
US61/118,969 | 2008-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010131172A true RU2010131172A (en) | 2012-02-10 |
Family
ID=45852991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010131172/15A RU2010131172A (en) | 2007-12-27 | 2008-12-23 | THERAPEUTIC METHODS FOR TREATING CANCER |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2010131172A (en) |
-
2008
- 2008-12-23 RU RU2010131172/15A patent/RU2010131172A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oronsky et al. | What's new in SCLC? A review | |
Brosnan et al. | Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies | |
Ohtsu et al. | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | |
JP2011522773A5 (en) | ||
Eckhardt | Recent progress in the development of anticancer agents | |
TW201615191A (en) | The new cancer therapy indication of the amlodipine besylate | |
Fernando et al. | The principles of cancer treatment by chemotherapy | |
RU2009136992A (en) | NANOPARTICLE CONTAINING RAMAMIC AND ALBUMIN AS ANTI-CANCER AGENT | |
Mountzios et al. | Developments in the systemic treatment of metastatic cervical cancer | |
RU2017104909A (en) | CANCER TREATMENT WITH A COMBINATION OF RADIATION THERAPY, CERIUM OXIDE NANOPARTICLES AND CHEMOTHERAPEUTIC | |
WO2007106503A3 (en) | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors | |
CN103460050A (en) | Marker for determination of sensitivity to anticancer agent | |
RU2010151602A (en) | COMBINED THERAPY USING PM00104 AND ANOTHER ANTITUM AGENT | |
Chabner | General principles of cancer chemotherapy | |
Jones | Cytotoxic chemotherapy: clinical aspects | |
JP2019514864A (en) | Method of treating liver cancer | |
JP2018194556A (en) | Combination anti-cancer agent sensitivity determining marker | |
Bonavida et al. | Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy | |
JP2011520921A5 (en) | ||
RU2013131168A (en) | AGTR1 AS A MARKER FOR COMBINED THERAPIES USING BEVACISUMAB | |
Dickens et al. | Principles of cancer treatment by chemotherapy | |
AU2014317117A1 (en) | Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors | |
CA2902144A1 (en) | Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
JP2016505043A5 (en) | ||
Wu et al. | A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130507 |